Clinical observation on the changes of T lymphocytes subgroups and NK cells in peripheral blood of patients with endometrial cancer treated with CIK cells

Objective:To observe the clinical efficacy of cytokine-induced killer(CIK) cells combined with chemotherapy,endocrine therapy for endometrial cancer.Methods:Thirty-five patients with endometrial cancer were treated with biotherapy of CIK cells for 6 courses of treatment,including 11 patients treated with chemotherapy(taxol and platinol) combined with biotherapy of CIK cells,15 patients treated with endocrine therapy of megestrol acetate combined with biotherapy of CIK cells,and 9 patients treated with simple biotherapy of CIK cells.The changes of CD3+ lymphocytes subgroup,CD4+ lymphocytes subgroup,the ratio of CD4+/CD8+,proportion of NK cells,and KPS scores before and after treatment were detected by flow cytometry,then the results were analyzed retrospectively.Results:After treatment,CD3+ cells of 35 patients with endometrial cancer didn't change significantly,CD4+ helper T lymphocytes increased significantly,the ratio of CD4+/CD8+ increased significantly,CD3-/CD16+56+ cells of some patients increased after treatment,but there was no statistically significant difference between before and after treatment,the mean KPS score after treatment increased by 10(P0.05).Conclusion:CIK cells can improve the immune function and general status of patients with endometrial cancer.